Therapeutic nutrition for Crohn’s disease
https://doi.org/10.31146/1682-8658-ecg-234-2-194-206
Abstract
Crohn’s disease is a chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract (from the mouth to the anus).Malnutrition affects 65-75% of patients with Crohn’s disease, and it is now generally accepted that diet is of primary importance in the treatment of the disease.In this review, we would like to highlight the most recent discoveries in the field of nutrition for the treatment of Crohn’s disease.Our analysis will cover a wide range of topics, from established diets to new nutritional theories, as well as recent progress in new research areas such as nutrigenomics.
About the Authors
Z. Kh. Gulunov
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Ya. V. Sousova
St. Petersburg State Pediatric Medical University; Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
N. G. Korbesova
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
References
1. Damas O.M., Garces L., Abreu M.T. Diet as Adjunctive Treatment for Inflammatory Bowel Disease: Review and Update of the Latest Literature. Curr Treat Options Gastroenterol. 2019 Jun;17(2):313-325. doi: 10.1007/s11938-019-00231-8.
2. Uspenskiy Yu.P., Gulunov Z. Kh., Korbesova N.G. Crohn’s disease: lesion of the esophagus, stomach and duodenum. University Therapeutic Journal. 2024;6(2):32-45. (in Russ.) doi: 10.56871/UTJ.2024.32.24.004.
3. Успенский Ю.П., Гулунов З.Х., Корбесова Н.Г. Болезнь Крона: поражение пищевода, желудка и двенадцатиперстной кишки. Университетский терапевтический вестник. 2024. Т. 6. No 2. С. 32-45. doi: 10.56871/UTJ.2024.32.24.004.
4. Uspensky Yu.P., Dreval R.O., Ivanov S.V. Crohn’s disease: pharmacoeconomic aspects of patient management. University Therapeutic Bulletin. 2021;2(1):98-99. (in Russ.)
5. Успенский Ю.П., Древаль Р.О. Иванов С.В. Болезнь Крона: фармакоэкономические аспекты ведения пациентов. Университетский терапевтический вестник. 2021;2(1):98-99.
6. Uspenskiy Yu.P., Fominykh Yu.A., Ivanov S.V. et al. Differential diagnosis of immunoinfl ammatory lesions of the colon in ulcerative colitis and Crohn’s disease in the early period of the disease course: clinical, endoscopic and histological features. University Therapeutic Journal. 2024;6(2):82-96. (in Russ.) doi: 10.56871/UTJ.2024.84.96.010.
7. Успенский Ю.П., Фоминых Ю.А., Иванов С.В. и др. Дифференциальная диагностика иммуновоспалительного поражения толстой кишки при язвенном колите и болезни Крона в раннем периоде течения заболевания: клинические, эндоскопические и гистологические аспекты. Университетский терапевтический вестник. 2024;6(2):82-96. doi: 10.56871/UTJ.2024.84.96.010.
8. Budzinskaya A.A., Belousova E.A., Tereschenko S.G., Levitskaya A.V. Ulcerative colitis and Crohn’s disease: problems of differential diagnosis. University therapeutic journal (St. Petersburg). 2023;5(3):31-40. (in Russ.) doi: 10.56871/UTJ.2023.92.54.003.
9. Будзинская А.А., Белоусова Е.А., Терещенко С.Г., Левитская А.В. Язвенный колит и болезнь Крона: проблемы дифференциальной диагностики. Университетский терапевтический вестник. 2023;5(3):31-40. doi: 10.56871/UTJ.2023.92.54.003.
10. Torres J., Mehandru S., Colombel J.F., Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017 Apr 29;389(10080):1741-1755. doi: 10.1016/S0140-6736(16)31711-1.
11. Uspenskiy Yu.P., Ivanov S.V., Fominykh Yu.A., Segal A.M., Magomedova A.M. Features of the complicated course and extraintestinal manifestations of inflammatory bowel diseases. University therapeutic journal (St. Petersburg). 2023; 5(2): 68-83. (in Russ.) doi: 10.56871/UTJ.2023.72.18.006.
12. Успенский Ю.П., Иванов С.В., Фоминых Ю.А., Сегаль А.М., Магомедова А.М. Особенности осложненного течения и внекишечных проявлений воспалительных заболеваний кишечника. Университетский терапевтический вестник. 2023; 5(2): 68-83. doi: 10.56871/UTJ.2023.72.18.006.
13. Jostins L., Ripke S., Weersma R.K. et al; International IBD Genetics Consortium (IIBDGC); Silverberg M.S., Annese V., Hakonarson H. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov 1;491(7422):119-24. doi: 10.1038/nature11582.
14. Kostic A.D., Xavier R.J., Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014 May;146(6):1489-99. doi: 10.1053/j.gastro.2014.02.009.
15. Bernink J.H., Peters C.P., Munneke M. et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013 Mar;14(3):221-9. doi: 10.1038/ni.2534.
16. Geremia A., Arancibia-Cárcamo C.V., Fleming M.P. et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011 Jun 6;208(6):1127-33. doi: 10.1084/jem.20101712.
17. Laube R., Liu K., Schifter M., Yang J.L., Suen M.K., Leong R.W. Oral and upper gastrointestinal Crohn’s disease. J Gastroenterol Hepatol. 2018 Feb;33(2):355-364. doi: 10.1111/jgh.13866.
18. Scaldaferri F., Pizzoferrato M., Lopetuso L.R. et al. Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide. Gastroenterol Res Pract. 2017;2017: 8646495. doi: 10.1155/2017/8646495.
19. Laing B., Han D.Y., Ferguson L.R. Candidate genes involved in beneficial or adverse responses to commonly eaten brassica vegetables in a New Zealand Crohn’s disease cohort. Nutrients. 2013 Dec 12;5(12):5046-64. doi: 10.3390/nu5125046.
20. Zoli G., Katelaris P.H., Garrow J., Gasbarrini G., Farthing M.J. Increased energy expenditure in growing adolescents with Crohn’s disease. Dig Dis Sci. 1996 Sep;41(9):1754-9. doi: 10.1007/BF02088741.
21. Heerasing N., Thompson B., Hendy P. et al. Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn’s disease. Aliment Pharmacol Ther. 2017 Mar;45(5):660-669. doi: 10.1111/apt.13934.
22. Ayoub F., Kamel A.Y., Ouni A. et al. Pre-operative total parenteral nutrition improves post-operative outcomes in a subset of Crohn’s disease patients undergoing major abdominal surgery. Gastroenterol Rep (Oxf). 2019 Apr;7(2):107-114. doi: 10.1093/gastro/goy033.
23. Fumery M., Seksik P., Auzolle C. et al; REMIND study group investigators. Postoperative Complications after Ileocecal Resection in Crohn’s Disease: A Prospective Study From the REMIND Group. Am J Gastroenterol. 2017 Feb;112(2):337-345. doi: 10.1038/ajg.2016.541.
24. Adamina M., Bonovas S., Raine T. et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. J Crohns Colitis. 2020 Feb 10;14(2):155-168. doi: 10.1093/ecco-jcc/jjz187.
25. Di Caro S., Fragkos K.C., Keetarut K. et al. Enteral Nutrition in Adult Crohn’s Disease: Toward a Paradigm Shift. Nutrients. 2019 Sep 14;11(9):2222. doi: 10.3390/nu11092222.
26. Yamamoto T., Shimoyama T., Kuriyama M. Dietary and enteral interventions for Crohn’s disease. Curr Opin Biotechnol. 2017 Apr;44:69-73. doi: 10.1016/j.copbio.2016.11.011.
27. Critch J., Day A.S., Otley A., King-Moore C., Teitelbaum J.E., Shashidhar H; NASPGHAN IBD Committee. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2012 Feb;54(2):298-305. doi: 10.1097/MPG.0b013e318235b397.
28. Green N., Miller T., Suskind D., Lee D. A Review of Dietary Therapy for IBD and a Vision for the Future. Nutrients. 2019 Apr 26;11(5):947. doi: 10.3390/nu11050947.
29. Wall C.L., Day A.S., Gearry R.B. Use of exclusive enteral nutrition in adults with Crohn’s disease: a review. World J Gastroenterol. 2013 Nov 21;19(43):7652-60. doi: 10.3748/wjg.v19.i43.7652.
30. Thursby E., Juge N.Introduction to the human gut microbiota. Biochem J. 2017 May 16;474(11):1823-1836. doi: 10.1042/BCJ20160510.
31. Schwerd T., Frivolt K., Clavel T. et al. Exclusive enteral nutrition in active pediatric Crohn disease: Effects on intestinal microbiota and immune regulation. J Allergy Clin Immunol. 2016 Aug;138(2):592-6. doi: 10.1016/j.jaci.2015.12.1331.
32. Quince C., Ijaz U.Z., Loman N. et al. Extensive Modulation of the Fecal Metagenome in Children With Crohn’s Disease During Exclusive Enteral Nutrition. Am J Gastroenterol. 2015 Dec;110(12):1718-29; quiz 1730. doi: 10.1038/ajg.2015.357.
33. Zoli G., Carè M., Parazza M., Spanò C., Biagi P.L., Bernardi M., Gasbarrini G. A randomized controlled study comparing elemental diet and steroid treatment in Crohn’s disease. Aliment Pharmacol Ther. 1997 Aug;11(4):735-40. doi: 10.1046/j.1365-2036.1997.t01-1-00192.x.
34. Limketkai B.N., Wolf A., Parian A.M. Nutritional Interventions in the Patient with Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2018 Mar;47(1):155-177. doi: 10.1016/j.gtc.2017.09.007.
35. Adamina M., Gerasimidis K., Sigall-Boneh R. et al. Perioperative Dietary Therapy in Inflammatory Bowel Disease. J Crohns Colitis. 2020 May 21;14(4):431-444. doi: 10.1093/ecco-jcc/jjz160.
36. Braga M., Ljungqvist O., Soeters P., Fearon K., Weimann A., Bozzetti F; ESPEN. ESPEN Guidelines on Parenteral Nutrition: surgery. Clin Nutr. 2009 Aug;28(4):378-86. doi: 10.1016/j.clnu.2009.04.002.
37. Jacobson S. Early postoperative complications in patients with Crohn’s disease given and not given preoperative total parenteral nutrition. Scand J Gastroenterol. 2012 Feb;47(2):170-7. doi: 10.3109/00365521.2011.648954.
38. Greenberg G.R., Fleming C.R., Jeejeebhoy K.N., Rosenberg I.H., Sales D., Tremaine W.J. Controlled trial of bowel rest and nutritional support in the management of Crohn’s disease. Gut. 1988 Oct;29(10):1309-15. doi: 10.1136/gut.29.10.1309.
39. Ockenga J., Borchert K., Stüber E., Lochs H., Manns M.P., Bischoff S.C. Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. Eur J Clin Nutr. 2005 Nov;59(11):1302-9. doi: 10.1038/sj.ejcn.1602243.
40. Yamamoto T., Nakahigashi M., Shimoyama T., Umegae S. Does preoperative enteral nutrition reduce the incidence of surgical complications in patients with Crohn’s disease? A case-matched study. Colorectal Dis. 2020 May;22(5):554-561. doi: 10.1111/codi.14922.
41. Li G., Ren J., Wang G., Hu D., Gu G., Liu S., Ren H., Wu X., Li J. Preoperative exclusive enteral nutrition reduces the postoperative septic complications of fistulizing Crohn’s disease. Eur J Clin Nutr. 2014 Apr;68(4):441-6. doi: 10.1038/ejcn.2014.16.
42. Weimann A., Braga M., Carli F. et al. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr. 2017 Jun;36(3):623-650. doi: 10.1016/j.clnu.2017.02.013.
43. Heyland D.K., Montalvo M., MacDonald S., Keefe L., Su X.Y., Drover J.W. Total parenteral nutrition in the surgical patient: a meta-analysis. Can J Surg. 2001 Apr;44(2):102-11. PMID: 11308231.
44. Braunschweig C.L., Levy P., Sheean P.M., Wang X. Enteral compared with parenteral nutrition: a meta-analysis. Am J Clin Nutr. 2001 Oct;74(4):534-42. doi: 10.1093/ajcn/74.4.534.
45. Peter J.V., Moran J.L., Phillips-Hughes J. A metaanalysis of treatment outcomes of early enteral versus early parenteral nutrition in hospitalized patients. Crit Care Med. 2005 Jan;33(1):213-20; discussion 260-1. doi: 10.1097/01.ccm.0000150960.36228.c0.
46. Klek S., Forbes A., Gabe S. et al. Management of acute intestinal failure: A position paper from the European Society for Clinical Nutrition and Metabolism (ESPEN) Special Interest Group. Clin Nutr. 2016 Dec;35(6):1209-1218. doi: 10.1016/j.clnu.2016.04.009.
47. Kakodkar S., Mutlu E.A. Diet as a Therapeutic Option for Adult Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2017 Dec;46(4):745-767. doi: 10.1016/j.gtc.2017.08.016.
48. Kakodkar S., Farooqui A.J., Mikolaitis S.L., Mutlu E.A. The Specific Carbohydrate Diet for Inflammatory Bowel Disease: A Case Series. J Acad Nutr Diet. 2015 Aug;115(8):1226-32. doi: 10.1016/j.jand.2015.04.016.
49. Obih C., Wahbeh G., Lee D. et al. Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. Nutrition. 2016 Apr;32(4):418-25. doi: 10.1016/j.nut.2015.08.025.
50. Halmos E.P., Christophersen C.T., Bird A.R., Shepherd S.J., Muir J.G., Gibson P.R. Consistent Prebiotic Effect on Gut Microbiota With Altered FODMAP Intake in Patients with Crohn’s Disease: A Randomised, Controlled Cross-Over Trial of Well-Defined Diets. Clin Transl Gastroenterol. 2016 Apr 14;7(4): e164. doi: 10.1038/ctg.2016.22.
51. Chiba M., Abe T., Tsuda H., Sugawara T., Tsuda S., Tozawa H., Fujiwara K., Imai H. Lifestyle-related disease in Crohn’s disease: relapse prevention by a semi-vegetarian diet. World J Gastroenterol. 2010 May 28;16(20):2484-95. doi: 10.3748/wjg.v16.i20.2484.
52. Sandefur K., Kahleova H., Desmond A.N., Elfrink E., Barnard N.D. Crohn’s Disease Remission with a Plant-Based Diet: A Case Report. Nutrients. 2019 Jun 20;11(6):1385. doi: 10.3390/nu11061385.
53. Chiba M., Tsuji T., Nakane K., Komatsu M. High amount of dietary fiber not harmful but favorable for Crohn disease. Perm J. 2015 Winter;19(1):58-61. doi: 10.7812/TPP/14-124.
54. Shah A., Walker M., Burger D. et al. Link Between Celiac Disease and Inflammatory Bowel Disease. J Clin Gastroenterol. 2019 Aug;53(7):514-522. doi: 10.1097/MCG.0000000000001033.
55. Herfarth H.H., Martin C.F., Sandler R.S., Kappelman M.D., Long M.D. Prevalence of a gluten-free diet and improvement of clinical symptoms in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2014 Jul;20(7):1194-7. doi: 10.1097/MIB.0000000000000077.
56. Schreiner P., Yilmaz B., Rossel J.B. et al; Swiss IBD Cohort Study Group. Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease. United European Gastroenterol J. 2019 Jul;7(6):767-781. doi: 10.1177/2050640619841249.
57. Triantafillidis J.K., Tzouvala M., Triantafyllidi E. Enteral Nutrition Supplemented with Transforming Growth Factor-β, Colostrum, Probiotics, and Other Nutritional Compounds in the Treatment of Patients with Inflammatory Bowel Disease. Nutrients. 2020 Apr 10;12(4):1048. doi: 10.3390/nu12041048.
58. Pace F., Pace M., Quartarone G. Probiotics in digestive diseases: focus on Lactobacillus GG. Minerva Gastroenterol Dietol. 2015 Dec;61(4):273-92. PMID: 26657927.
59. Bjarnason I., Sission G., Hayee B. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology. 2019 Jun;27(3):465-473. doi: 10.1007/s10787-019-00595-4.
60. Derwa Y., Gracie D.J., Hamlin P.J., Ford A.C. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Aug;46(4):389-400. doi: 10.1111/apt.14203.
61. Fedorak R.N., Feagan B.G., Hotte N. et al. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease. Clin Gastroenterol Hepatol. 2015 May;13(5):928-35.e2. doi: 10.1016/j.cgh.2014.10.031.
62. Bousvaros A., Guandalini S., Baldassano R.N. et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis. 2005 Sep;11(9):833-9. doi: 10.1097/01.mib.0000175905.00212.2c.
63. Yılmaz İ., Dolar M.E., Özpınar H. Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: A randomized controlled trial. Turk J Gastroenterol. 2019 Mar;30(3):242-253. doi: 10.5152/tjg.2018.18227.
64. Benjamin J.L., Hedin C.R., Koutsoumpas A. et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut. 2011 Jul;60(7):923-9. doi: 10.1136/gut.2010.232025.
65. Steed H., Macfarlane G.T., Blackett K.L., Bahrami B., Reynolds N., Walsh S.V., Cummings J.H., Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn’s disease. Aliment Pharmacol Ther. 2010 Oct;32(7):872-83. doi: 10.1111/j.1365-2036.2010.04417.x.
66. Ferguson J.F., Allayee H., Gerszten R.E., Ideraabdullah F., Kris-Etherton P.M., Ordovás J.M., Rimm E.B., Wang T.J., Bennett B.J; American Heart Association Council on Functional Genomics and Translational Biology, Council on Epidemiology and Prevention, and Stroke Council. Nutrigenomics, the Microbiome, and Gene-Environment Interactions: New Directions in Cardiovascular Disease Research, Prevention, and Treatment: A Scientific Statement From the American Heart Association. Circ Cardiovasc Genet. 2016 Jun;9(3):291-313. doi: 10.1161/HCG.0000000000000030.
67. Bennike T., Birkelund S., Stensballe A., Andersen V. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J Gastroenterol. 2014 Mar 28;20(12):3231-44. doi: 10.3748/wjg.v20.i12.3231.
68. Goyette P., Boucher G., Mallon D. et al; International Inflammatory Bowel Disease Genetics Consortium; Australia and New Zealand IBDGC; Belgium IBD Genetics Consortium; Italian Group for IBD Genetic Consortium; NIDDK Inflammatory Bowel Disease Genetics Consortium; United Kingdom IBDGC; Wellcome Trust Case Control Consortium; Quebec IBD Genetics Consortium; Daly M.J., Van Steen K., Duerr R.H. et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet. 2015 Feb;47(2):172-9. doi: 10.1038/ng.3176.
69. Gruber L., Lichti P., Rath E., Haller D. Nutrigenomics and nutrigenetics in inflammatory bowel diseases. J Clin Gastroenterol. 2012 Oct;46(9):735-47. doi: 10.1097/MCG.0b013e31825ca21a.
70. Lin C.H., Chao L.K., Hung P.H., Chen Y.J. EGCG inhibits the growth and tumorigenicity of nasopharyngeal tumor-initiating cells through attenuation of STAT3 activation.Int J Clin Exp Pathol. 2014 Apr 15;7(5):2372-81. PMID: 24966947.
71. Maslowski K.M., Vieira A.T., Ng A. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009 Oct 29;461(7268):1282-6. doi: 10.1038/nature08530.
72. Sivaprakasam S., Gurav A., Paschall A.V. et al. An essential role of Ffar2 (Gpr43) in dietary fibre-mediated promotion of healthy composition of gut microbiota and suppression of intestinal carcinogenesis. Oncogenesis. 2016 Jun 27;5(6): e238. doi: 10.1038/oncsis.2016.38.
73. Petermann I., Triggs C.M., Huebner C. et al. Mushroom intolerance: a novel diet-gene interaction in Crohn’s disease. Br J Nutr. 2009 Aug;102(4):506-8. doi: 10.1017/S0007114509276446.
74. Kim M.J., Kim W.S., Kim D.O. et al. Macrophage migration inhibitory factor interacts with thioredoxin-interacting protein and induces NF-κB activity. Cell Signal. 2017 Jun;34:110-120. doi: 10.1016/j.cellsig.2017.03.007.
75. Broussard J.L., Devkota S. The changing microbial landscape of Western society: Diet, dwellings and discordance. Mol Metab. 2016 Jul 21;5(9):737-42. doi: 10.1016/j.molmet.2016.07.007.
76. Cooney J.M., Barnett M.P., Brewster D., Knoch B., McNabb W.C., Laing W.A., Roy N.C. Proteomic analysis of colon tissue from interleukin-10 gene-deficient mice fed polyunsaturated Fatty acids with comparison to transcriptomic analysis. J Proteome Res. 2012 Feb 3;11(2):1065-77. doi: 10.1021/pr200807p.
77. Hume G.E., Fowler E.V., Griffiths L.R., Doecke J.D., Radford-Smith G.L.Common PPARγ variants C161T and Pro12Ala are not associated with inflammatory bowel disease in an Australian cohort. J Gastrointestin Liver Dis. 2012 Dec;21(4):349-55. PMID: 23256116.
78. Barua A.B., Olson J.A. beta-carotene is converted primarily to retinoids in rats in vivo. J Nutr. 2000 Aug;130(8):1996-2001. doi: 10.1093/jn/130.8.1996.
79. Leung W.C., Hessel S., Méplan C. et al. Two common single nucleotide polymorphisms in the gene encoding beta-carotene 15,15’-monoxygenase alter beta-carotene metabolism in female volunteers. FASEB J. 2009 Apr;23(4):1041-53. doi: 10.1096/fj.08-121962.
80. Laing B.B., Lim A.G., Ferguson L.R. A Personalised Dietary Approach-A Way Forward to Manage Nutrient Deficiency, Effects of the Western Diet, and Food Intolerances in Inflammatory Bowel Disease. Nutrients. 2019 Jul 5;11(7):1532. doi: 10.3390/nu11071532.
81. Fernández-Ponce C., Navarro Quiroz R., Díaz Perez A. et al. MicroRNAs overexpressed in Crohn’s disease and their interactions with mechanisms of epigenetic regulation explain novel aspects of Crohn’s disease pathogenesis. Clin Epigenetics. 2021 Feb 18;13(1):39. doi: 10.1186/s13148-021-01022-8.
82. Krissansen G.W., Yang Y., McQueen F.M. et al. Overexpression of miR-595 and miR-1246 in the sera of patients with active forms of inflammatory bowel disease. Inflamm Bowel Dis. 2015 Mar;21(3):520-30. doi: 10.1097/MIB.0000000000000285.
83. Simopoulos A.P. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr. 1991 Sep;54(3):438-63. doi: 10.1093/ajcn/54.3.438.
84. Wacklin P., Mäkivuokko H., Alakulppi N. et al. Secretor genotype (FUT2 gene) is strongly associated with the composition of Bifidobacteria in the human intestine. PLoS One. 2011;6(5): e20113. doi: 10.1371/journal.pone.0020113.
85. Milani C., Duranti S., Bottacini F. et al. The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota. Microbiol Mol Biol Rev. 2017 Nov 8;81(4): e00036-17. doi: 10.1128/MMBR.00036-17.
86. Mishkin S. Dairy sensitivity, lactose malabsorption, and elimination diets in inflammatory bowel disease. Am J Clin Nutr. 1997 Feb;65(2):564-7. doi: 10.1093/ajcn/65.2.564.
87. Enattah N.S., Sahi T., Savilahti E., Terwilliger J.D., Peltonen L., Järvelä I. Identification of a variant associated with adult-type hypolactasia. Nat Genet. 2002 Feb;30(2):233-7. doi: 10.1038/ng826.
88. Nolan D.J., Han D.Y., Lam W.J., Morgan A.R., Fraser A.G., Tapsell L.C., Ferguson L.R. Genetic adult lactase persistence is associated with risk of Crohn’s Disease in a New Zealand population. BMC Res Notes. 2010 Dec 19;3:339. doi: 10.1186/1756-0500-3-339.
Review
For citations:
Gulunov Z.Kh., Sousova Ya.V., Korbesova N.G. Therapeutic nutrition for Crohn’s disease. Experimental and Clinical Gastroenterology. 2025;(2):194-206. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-234-2-194-206
Views:
8
Email this article 